# Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib

> **NCT06620835** · PHASE2 · RECRUITING · sponsor: **Groupe Francais De Pneumo-Cancerologie** · enrollment: 45 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **BIOLOGICAL:** Blood samples for Hematology
- **BIOLOGICAL:** Blood samples for Chemistry
- **BIOLOGICAL:** Blood sample for liver function tests
- **BIOLOGICAL:** Pregnancy test
- **PROCEDURE:** Tumour assessment
- **PROCEDURE:** Local Ablative Therapy (LAT)

## Key facts

- **NCT ID:** NCT06620835
- **Lead sponsor:** Groupe Francais De Pneumo-Cancerologie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-19
- **Primary completion:** 2030-10-01
- **Final completion:** 2030-10-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06620835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06620835, "Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT06620835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*